Therapeutic Effects of Biobran, Modified Arabinoxylan Rice Bran, in Improving Symptoms of Diarrhea Predominant or Mixed Type Irritable Bowel Syndrome: A Pilot, Randomized Controlled Study
Table 4
Changes in values of hematological and serological examinations between baseline and after 4 weeks of treatment.
Baseline
Treatment
White blood cell ()
Biobran
59.9 ± 17.0
58.7 ± 15.8
N.S.
Placebo
63.8 ± 18.3
60.7 ± 14.7
N.S.
Neutrophil (%)
Biobran
58.1 ± 8.1
54.3 ± 6.8*
0.039
Placebo
60.5 ± 8.3
60.3 ± 7.9
N.S.
Lymphocyte (%)
Biobran
32.0 ± 7.4
35.5 ± 6.2**
0.022
Placebo
29.8 ± 7.0
30.3 ± 7.5
N.S.
Hemoglobin (g/dl)
Biobran
13.6 ± 1.2
13.8 ± 1.3
N.S.
Placebo
14.0 ± 1.9
13.8 ± 2.1
N.S.
Platelet count
Biobran
19.5 ± 5.7
21.9 ± 4.7
N.S.
Placebo
23.2 ± 5.5
21.4 ± 5.2
0.011
CRP (g/dl)
Biobran
0.12 ± 0.10
0.10 ± 0.13
0.042
Placebo
0.32 ± 0.47
0.25 ± 0.36
N.S.
NOR
Biobran
445.8 ± 166.1
508.6 ± 179.5
N.S.
Placebo
412.6 ± 183.0
389.3 ± 140.1
N.S.
T cell (%)
Biobran
87.9 ± 3.6
86.9 ± 4.7
N.S.
Placebo
87.1 ± 4.6
86.9 ± 3.7
N.S.
B cell (%)
Biobran
5.28 ± 2.49
6.44 ± 2.75
0.042
Placebo
5.84 ± 2.52
5.28 ± 2.87
N.S.
NK cell activity (%)
Biobran
31.7 ± 12.5
40.3 ± 15.7
0.002
Placebo
36.2 ± 15.4
35.6 ± 15.7
N.S.
Th1/Th2
Biobran
9.92 ± 5.60
10.05 ± 5.99
N.S.
Placebo
8.71 ± 5.31
10.24 ± 7.21
N.S.
Values are mean ± SD; versus Placebo; versus Placebo. CRP, C reactive protein; NOR, Noradrenalin.
